ReviewThe American journal of pathology1998
Androgen receptor gene and hormonal therapy failure of prostate cancer.
Review in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 193 citations in OpenAlex.
- Review
- Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants.Biomedicines · 2023Review
- Androgen receptor contributes to repairing DNA damage induced by inflammation and oxidative stress in prostate cancer.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Article
- Review
- Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor.Oncogenesis · 2020Article
- Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.Oncogene · 2019Article
- Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.Antioxidants & redox signaling · 2019Article
- Article
- Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.World journal of clinical oncology · 2016Review
- Androgen receptor gene mutation, rearrangement, polymorphism.Translational andrology and urology · 2013Article
- Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.International journal of molecular sciences · 2013Article
- Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.The Journal of biological chemistry · 2011Article
- The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.Biology direct · 2010Article
- Redefining hormone resistance in prostate cancer.Therapeutic advances in medical oncology · 2010Article
- Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.Cell cycle (Georgetown, Tex.) · 2009Article
- Anti-proliferation Effect of Polypeptide Extracted from Scorpion Venom on Human Prostate Cancer Cells in vitro.Journal of clinical medicine research · 2009Article
- Transcription factors: their potential as targets for an individualized therapeutic approach to cancer.Cancer gene therapy · 2009Review
- Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Prostate cancer stem cells.The Journal of pathology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen receptor (AR) is a nuclear transcription factor that binds male sex steroids and mediates the biological effects of these hormones to the target cells, such as the epithelial cells of the prostate gland, by activating transcription of androgen-dependent genes. Withdrawal of androgens or the peripheral blockade of androgen action remain the critical therapeutic options for the treatment of advanced prostate cancer. However, after initial regression, many prostate cancers become hormone refractory and progress further with eventual fatal outcome. Understanding the mechanisms of tumor progression and endocrine therapy failure is an important goal. A large number of different molecular mechanisms may be responsible for development of hormone-refractory recurrent tumors. Many of these involve the AR gene and its complex downstream signaling pathways. The role of AR mutations and altered transactivational properties of the receptor have received the most attention as causative factors for progression. However, other mechanisms, such as AR gene amplification and overexpression or increased local bioconversion of androgens, may contribute to the development of progression by mechanisms that involve androgen-dependent cell growth. Here we review the role of the AR gene and its putative downstream effector pathways during human prostate cancer progression and endocrine therapy failure.
Indexed as
Identifiers
9422516PMC1858130W1536788832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.